Congenital Heart Disease (CHD) market

1. Congenital Heart Disease (CHD) Market Trends, Size, Share, Demands, Overview, Growth, Revenue and Forecast to 2030 sales@delvens.comwww.delvens.com

2. Sternal Closure Systems Market – Trends Forecast Till 2030 Congenital Heart Disease (CHD) Market, by Type (Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Others), Diagnosis (Electrocardiogram, Chest X-ray, Echocardiogram, Transoesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac CT Scan or MRI, Cardiac Catheterization, Other), Treatment (Medications, Surgery, Watchful Waiting, Others), Route of Administration (Oral, Parenteral, Others), End Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America). Request For Free Sample Report: https://www.delvens.com/get-free-sample/congenital-heart-disease-chd-market sales@delvens.com www.delvens.com

3. Market Overview Congenital Heart Disease (CHD) is a term used to describe a range of structural defects in the heart that are present at birth. These defects can involve the walls, valves, arteries, or veins of the heart, causing problems with blood flow and affecting the heart’s ability to pump blood effectively. Some congenital heart defects are mild and may not require treatment, while others can be more severe and require medical interventions such as surgery or medication. The exact cause of most congenital heart defects is not known, but a combination of genetic and environmental factors is thought to play a role. The growth of the global Congenital Heart Disease (CHD) market is mainly driven by rising prevalence of congenital heart disease globally. Moreover, increased awareness, improved diagnostic techniques, increased awareness and better access to healthcare are expected to drive the market further. In addition, the growing emphasis on paediatric cardiology and specialized care for children are expected to drive the market further during the forecast period. Purchase this Report: https://www.delvens.com/checkout/congenital-heart-disease-chd-market sales@delvens.com www.delvens.com

4. Key Findings The Congenital Heart Disease (CHD) Market is segmented into Type, diagnosis, treatment, route of administration, end users, distribution channel, and region: Based on type, the market is segmented into heart valve defects, heart wall defects, blood vessel defects, others. The heart wall defects dominated the market in this segment. This is due to the increase in the cases of Ventricular septal defect (VSD) or hole in the heart worldwide. Based on diagnosis, the market is bifurcated into electrocardiogram, chest x-ray, echocardiogram, transoesophageal echocardiogram, pulse oximetry, exercise stress test, cardiac CT scan or MRI, cardiac catheterization, others. Electrocardiogram dominated the market in this segment. This is because Electrocardiogram is the most common diagnostic tool to diagnose heart defects. sales@delvens.com www.delvens.com

5. Key Findings Based on treatment, the market is segmented into medications, surgery, watchful waiting, others. Surgery dominated the market in this segment as it is the most common treatment for CHD. Surgical treatment can be performed open-heart surgery or minimally invasive surgery. The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. Inquire Before Buying: https://www.delvens.com/Inquire-before-buying/congenital-heart-disease-chd-market sales@delvens.com www.delvens.com

6. Competitive Landscape • Abbott Laboratories • AstraZeneca Plc • Becton Dickson & Co. • Bio-Rad Laboratories • Boston Scientific Corp. • Laboratory Corporation of America Holdings (LabCorp) • F. Hoffmann-La Roche Ltd. • Glaxosmithkline Plc • Janssen Pharmaceuticals, Inc. • Medtronic • Viatris Inc. • Novartis Ag • Pfizer, Inc. • Randox Laboratories Ltd. • Response Biomedical Corporation • Sanofi S.A. • Siemens Healthineers • Thermo Fisher Scientific Inc. • Vericel Corporation sales@delvens.com www.delvens.com

7. Recent Developments In June 2023, Pfizer relaunched Eliquis, an anticoagulant used to prevent the gradual increase in the prevalence of stroke due to heart condition called atrial fibrillation which is a major concern being a common cause of death among adults. In July 2023, Novartis announced that the US Food and Drug Administration (FDA) approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy. sales@delvens.com www.delvens.com

8. Contact Information About Us: Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally. Contact Us: +44-20-3290-6466 +1 214-377-1144 sales@delvens.com sales@delvens.com www.delvens.com